Epstein-Barr virus (EBV) is a human herpesvirus that infects more than 90% of adults worldwide. While EBV usually causes a mild illness known as infectious mononucleosis, it is also associated with several cancers. Long-term infection of EBV has been linked to cancers like Burkitt's lymphoma, Hodgkin's lymphoma, NK/T-cell lymphoma, gastric carcinoma, and nasopharyngeal carcinoma.

Development of Monovaccine for EBV

Scientists at the University of Oxford have developed a potential vaccine called monovaccine that specifically targets EBV. The monovaccine consists of dendritic cells exposed to EBV antigens. Dendritic cells are key players in the immune system that capture antigens and present them to T cells to trigger an immune response. By using dendritic cells pulsed with EBV antigens, the researchers are aiming to induce T cell immunity against EBV.

In pre-clinical studies conducted in mice, the monovaccine showed promising results. When the mice were immunized with the EBV-pulsed dendritic cells, it induced robust and long-lasting EBV-specific T cell responses. The T cells were able to recognize and eliminate EBV-infected cells. Importantly, the vaccine prevented establishment of latent Epstein-Barr virus (EBV) infection in the mice. This proves that the monovaccine is able to generate immune memory against EBV and potentially protect against diseases linked to the virus.

Ongoing Clinical Trials

Encouraged by the pre-clinical findings, the researchers have initiated early phase clinical trials to evaluate the monovaccine in humans. So far, two Phase I clinical trials have been completed safely demonstrating that the vaccine is well-tolerated in humans and induces immunogenicity against EBV antigens.

In the ongoing Phase II clinical trial, the researchers are evaluating the ability of the monovaccine to reduce EBV load in patients with active EBV infection. 30 EBV-positive patients are being administered the monovaccine and their EBV viral load is being monitored over time using PCR tests. Any reduction in viral load achieved by the vaccine will indicate its potential to control infection. Results from this trial are expected by the end of 2023.

Besides controlling active infection, the long term goal is to test if the monovaccine can protect against EBV-driven diseases like nasopharyngeal carcinoma and lymphoma. Larger late phase studies will be planned to demonstrate clinical efficacy against these cancers.

Potential Impact and Challenges

If found effective, the monovaccine will be a landmark achievement in cancer prevention. It can potentially save thousands of lives lost annually to EBV-related cancers worldwide. Currently available therapies for these cancers have major limitations. A prophylactic vaccine that prevents EBV infection or controls viral latency could be a game changer.

However, developing an effective vaccine against EBV poses unique challenges. The virus establishes lifelong latency without being cleared by the immune system. Disrupting this latency while avoiding potential inflammatory responses will require optimizing the vaccine extensively. Safety will be a top priority in clinical studies. Manufacturing challenges for producing dendritic cell-based vaccines at scale also need addressing.

Despite obstacles, researchers are optimistic that lessons from other herpesvirus vaccines can help overcome problems. Continued research support is crucial for advancing the monovaccine through development. Success would open new possibilities for tackling other pathogens using this personalized medicine approach. Overall, the EBV monovaccine holds tremendous hope for cancer prevention but achieving this goal will require sustained effort.

Get More Insights Here

https://www.pressreleasebulletin.com/monovaccine-breakthrough-for-ebv/